research use only

Duloxetine HCl Serotonin Transporter Inhibitor

Name: Duloxetine HCl
Brand: Selleck Chemicals
SKU: S2084
Rating: 5 (5 reviews)

Cat.No.: S2084

Duloxetine HCl (LY-248686) is a serotonin-norepinephrine reuptake inhibitor with K_i of 4.6 nM, used for treatment of major depressive disorder and generalized anxiety disorder (GAD).

Chemical Structure

Molecular Weight: 333.88

Jump to

Quality Control

Batch: Purity: 99.89%

99.89

Related Targets	Adrenergic Receptor AChR 5-HT Receptor COX Calcium Channel Histamine Receptor Dopamine Receptor GABA Receptor TRP Channel Cholinesterase (ChE)
Other Serotonin Transporter Inhibitors	Dapoxetine

Chemical Information, Storage & Stability

Molecular Weight	333.88	Formula	C₁₈H₁₉NOS.HCl	Storage (From the date of receipt)	3 years-20°Cpowder
CAS No.	136434-34-9	Download SDF		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	LY-248686 HCl			Smiles	CNCCC(C1=CC=CS1)OC2=CC=CC3=CC=CC=C32.Cl

Solubility

In vitro
Batch:

DMSO : 67 mg/mL (200.67 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : 3 mg/mL

Ethanol : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
=	×	×

Dilution Calculator Molecular Weight Calculator

In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg Average weight of animals: g Dosing volume per animal:μL Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

Targets/IC₅₀/Ki	5-HT
References	[1] https://pubmed.ncbi.nlm.nih.gov/2850421/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2026-06-16)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT07649291	NOT_YET_RECRUITING	Knee Osteoarthritis; Pain; Depression	VA Office of Research and Development	2027-03-01	PHASE2
NCT07731750	NOT_YET_RECRUITING	Chronic Low-back Pain	University of Michigan	2026-07
NCT05851898	RECRUITING	Depression in Old Age; Fragility Fracture	Wake Forest University Health Sciences	2024-04-08	PHASE4
NCT07203339	RECRUITING	Fibromyalgia (FM); tDCS; Duloxetine; BDNF; EEG	Hospital de Clinicas de Porto Alegre	2025-09-30
NCT07759336	NOT_YET_RECRUITING	Knee Osteoarthritis (Knee OA); Chronic Pain; Chronic Knee Pain	Benedict Alter	2026-08	PHASE4
NCT06614322	RECRUITING	Painful Peripheral Neuropathy; Diabetic Peripheral Neuropathic Pain (DPN); Chemotherapy Induced Peripheral Neuropathy (CIPN); Idiopathic Peripheral Neuropathy	University of Rochester	2026-01-29	PHASE2

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):